Status:
COMPLETED
ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients
Lead Sponsor:
University Hospital, Lille
Conditions:
Immunocompromised Host
Critical Care
Eligibility:
All Genders
18+ years
Brief Summary
the number of immunocompromised patients hospitalized in the intensive care units (ICU) is increasing. They are at higher risk of colonization and/or infection with multi-resistant bacteria (MDR). How...
Eligibility Criteria
Inclusion
- Expected ICU stay \> 48 hours
- All patients (immunocompromised or immunocompetent).
Exclusion
- Patients aged \< 18 years
- Refusal to take part in the study
- ICU-stay \< 48 hours
- Non availability of initial MDR or subsequent screening
- Participation in another study that could interfere with the risk of ICU-acquired colonization and infection with MDR bacteria
Key Trial Info
Start Date :
November 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 7 2021
Estimated Enrollment :
759 Patients enrolled
Trial Details
Trial ID
NCT04043793
Start Date
November 7 2019
End Date
December 7 2021
Last Update
October 5 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens Picardie
Amiens, France
2
Ch Bethune
Béthune, France
3
Grand Hopital de L'Est Francilien
Jossigny, France
4
CH LENS
Lens, France